Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter Dose-Titration Open-Label Study of Nevanimibe Hydrochloride for the Treatment of Classic Congenital Adrenal Hyperplasia

Trial Profile

A Multicenter Dose-Titration Open-Label Study of Nevanimibe Hydrochloride for the Treatment of Classic Congenital Adrenal Hyperplasia

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nevanimibe (Primary)
  • Indications Congenital adrenal hyperplasia
  • Focus Therapeutic Use
  • Sponsors Millendo Therapeutics
  • Most Recent Events

    • 13 Nov 2019 According to a Millendo Therapeutics media release, top-line results from cohort 1 of this trial are expected in the second half of 2020.
    • 12 Aug 2019 According to a Millendo Therapeutics media release, the trial is now recruiting patients under an amended protocol. An update on the study timelines is planned for 2H19.
    • 12 Aug 2019 According to a Millendo Therapeutics media release, the protocol of this trial has been amended to include a 500 mg BID (twice a day) starting dose and an extension of the study treatment period to 16 weeks.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top